G. Pover - Concepedia

Author

G. Pover

AstraZeneca (United Kingdom)

Also Known As

G M Pover, G. M. Pover, G. Pover, G.M. Pover, Gillian M. Pover, Gillian Pover

Publications

878

Citations

H-Index

Concepts

All Affiliations

AstraZeneca (United Kingdom)National Institute of Oncology AstraZeneca (Brazil)Institute of Oncology Prof. Dr. Ion Chiricuta Groote Schuur Hospital

About

G. Pover is an author at AstraZeneca (United Kingdom) specializing in medicine, cancer therapeutics, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	624
2	Pharmacology	4	4	237
3	Health Sciences	3	3	414
4	Pathology	2	2	158
5	Cell Biology	1	1	27

G. Pover

Publications

838

Citations

H-Index

Page 1

	Year	Citations
A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy G. Bodoky, Constanta Timcheva, David R. Spigel, Investigational New Drugs Phase Ii Open-labelUrologyPancreatic CancerGastrointestinal OncologyMedicine	2011	228
A Phase II, Open-Label, Randomized Study to Assess the Efficacy and Safety of AZD6244 (ARRY-142886) Versus Pemetrexed in Patients with Non-small Cell Lung Cancer Who Have Failed One or Two Prior Chemotherapeutic Regimens John D. Hainsworth, C. Cebotaru, Vladimir Kanarev, Journal of Thoracic Oncology Phase IiAdvanced Lung DiseaseMedicineRandomized StudyVersus Pemetrexed	2010	159
A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens Jaafar Bennouna, István Láng, Manuel Valladares‐Ayerbes, Investigational New Drugs Phase IiGastrointestinal OncologyMedicinePharmacologyPathology	2010	139
A phase 1 dose escalation study of the oncolytic adenovirus enadenotucirev, administered intravenously to patients with epithelial solid tumors (EVOLVE) Jean‐Pascal Machiels, Ramón Salazar, Sylvie Rottey, Journal for ImmunoTherapy of Cancer	2019	100
Vandetanib with docetaxel as second-line treatment for advanced breast cancer: a double-blind, placebo-controlled, randomized Phase II study Katalin Boér, István Láng, Antonio Llombart‐Cussac, Investigational New Drugs Second-line TreatmentAdvanced Breast CancerBreast OncologyOncologyMedicine	2010	52
A Randomized, Double-Blind, Placebo-Controlled Phase II Study of Vandetanib Plus Docetaxel/Prednisolone in Patients with Hormone-Refractory Prostate Cancer J Horti, Anders Widmark, Arnulf Stenzl, Cancer Biotherapy and Radiopharmaceuticals	2009	49
Evaluation of a Breath Operated Powder Inhaler G. Pover, Cristóbal Langdon, Spencer Jones, Journal of International Medical Research	1988	37
Efficacy and safety of AZD6244 (ARRY-142886) as second/third-line treatment of patients (pts) with advanced non-small cell lung cancer (NSCLC) Valentina Tzekova, C. Cebotaru, Tudor–Eliade Ciuleanu, Journal of Clinical Oncology Chemoprevention StrategyPharmacotherapyTumor BiologyRadiation MedicineAnti-cancer Agent	2008	27
AZD6244 (ARRY-142886) versus capecitabine (CAP) in patients (pts) with metastatic colorectal cancer (mCRC) who have failed prior chemotherapy I. Láng, Antoine Adenis, Katalin Boér, Journal of Clinical Oncology Tumor BiologyAdverse EventsGastrointestinal OncologyMedicinePharmacology	2008	19
Long-term regularly inhaled salbutamol Kim Beswick, G. Pover, Shirlene Sampson Current Medical Research and Opinion	1986	18

Page 1